48th week of 2011 patent applcation highlights part 53 |
Patent application number | Title | Published |
20110294844 | 9-AMINONOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 2011-12-01 |
20110294845 | PARENTERAL FORMULATIONS - This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent. | 2011-12-01 |
20110294846 | INDOLE DERIVATIVES AS ANTICANCER AGENTS - The present invention provides compounds of formula (I), their use for the treatment of cancer as well as pharmaceutical compositions comprising said compounds of formula (I). | 2011-12-01 |
20110294847 | Novel Polymorphs Of Azabicyclohexane - The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms. | 2011-12-01 |
20110294848 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS - The invention provides potent quinolinol-based BoNT/A small-molecule inhibitors of botulinum neurotoxins, in particular of | 2011-12-01 |
20110294849 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE - The present invention relates to anhydrous and hydrated forms of Compound 1, which qre useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders. | 2011-12-01 |
20110294850 | INDOLINE DERIVATIVES - The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R | 2011-12-01 |
20110294851 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention relates to compounds of formula I: | 2011-12-01 |
20110294852 | Pharmaceutical Formulation Comprising Metformin and Repaglinide - The invention is related to a pharmaceutical composition comprising repaglinide in combination with metformin or a salt thereof in unit dosage form wherein a pre-formulation of the repaglinide has a pH independent dissolution profile and a relative humidity of less than about 25% prior to mixing with the metformin or a salt thereof; and optionally one or more pharmaceutically acceptable excipients and to a method for its preparation. | 2011-12-01 |
20110294853 | Bis Aromatic Compounds for Use in the Treatment of Inflammation - There is provided compounds of formula (I), wherein ring A, D | 2011-12-01 |
20110294854 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS - The present application relates to calcium channel inhibitors containing compounds of formula (I) | 2011-12-01 |
20110294855 | Active Compound Combinations - The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) the compound 3-(difluoromethyl)-N-[2-(1,1,2,3,3,3-hexafluoro propoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide of formula (I) and/or the compound 3-(di fluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide of formula (II) and (B) at least one azolylmethyloxirane of formula (III). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed. | 2011-12-01 |
20110294856 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE - This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2011-12-01 |
20110294857 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON - There is provided an inhibitor that inhibits casein kinase 1δ and casein kinase 1ε, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1δ or casein kinase 1ε is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. | 2011-12-01 |
20110294858 | SUBSTITUTED 6-METHYLNICOTINAMIDES AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS - In one aspect, the invention relates to substituted 6-methylnicotinamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2011-12-01 |
20110294859 | SUBSTITUTED PYRIDOXINE-LACTAM CARBOXYLATE SALTS - The present invention provides salt adducts comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, methods of their preparation, and pharmaceutical compositions and medicaments comprising them. Salt adducts of the invention and compositions comprising them may be used to in the treatment of diseases or disorders associated with or inflicted by alcohol consumption. | 2011-12-01 |
20110294860 | AQUEOUS ORAL PREPARATION OF STABLE AMLODIPINE - The invention provides a stable and rapidly disintegrable aqueous oral preparation (liquid or jelly preparation) of amlodipine. The liquid preparation comprises an anionic surfactant having a sulfuric acid group or a sulfonic acid group as a stabilizer in an aqueous solution of amlodipine, at pH 5-7, while the jelly preparation further comprises a gelling agent, a fine powder solid, and a gelling regulator. | 2011-12-01 |
20110294861 | METHOD OF TREATMENT OF HEREDITARY HEMOCHROMATOSIS - The present invention relates to the use of Compound I of the following formula | 2011-12-01 |
20110294862 | TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK - A method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof, and a method for the treatment of cardiopulmonary resuscitation, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof. | 2011-12-01 |
20110294863 | FUNGICIDE N-CYCLOALKYL-N-BICYCLIMETHYLENE-CARBOXAMIDE DERIVATIVES - The present invention relates N-cycloalkyl-N-bicyclicmethylene-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives of formula (I) wherein A represents a carbo-linked, 5-membered heterocyclyl group, T represents O or S, Z | 2011-12-01 |
20110294864 | AQUEOUS COACERVATE COMPOSITIONS SUITABLE FOR MAKING POWDERS AND WATER-SOLUBLE FORMULATIONS OF BIOLOGICALLY-ACTIVE AGENTS - Aqueous gel-free two-phase coacervate compositions including a coacervate phase and an equilibrium water phase, comprising a mixture of:
| 2011-12-01 |
20110294865 | METHODS OF DETECTING A FRAGMENT OF NEUROSECRETORY PROTEIN VGF FOR DIAGNOSING ALZHEIMER'S DISEASE - The present invention provides a neurosecretory protein VGF peptide useful in qualifying Alzheimer's disease status in a patient. In particular, this peptide and modified forms thereof may be used to classify a subject sample as Alzheimer's disease or non-Alzheimer's disease. The peptide biomarker can be detected by SELDI mass spectrometry. | 2011-12-01 |
20110294866 | PHARMACEUTICAL COMPOSITION FOR TREATING DEMENTIA COMPRISING SHRNA INHIBITING S100A9 EXPRESSION - Disclosed is a composition for treating dementia including shRNA to inhibit expression of S100a9. More particularly, the present disclosure describes a composition for prevention or treatment of dementia which includes shRNA having a nucleotide sequence defined by SEQ. ID No. 1 or 2 or a mixture thereof wherein the nucleotide sequence is complementarily bonded to mRNA of S100a9 in order to inhibit expression of S100a9, as well as a method for prevention or treatment of dementia, including administering the foregoing shRNA into a mammalian cell including a human cell or in vitro established mammalian cell-line, in order to inhibit expression of S100a9 protein. | 2011-12-01 |
20110294867 | SENSIZITATION OF CANCER CELLS TO THERAPY USING SINA TARGETING GENES FROM THE 1P AND 19Q CHROMOSOMAL REGIONS - The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region. | 2011-12-01 |
20110294868 | MODULATION OF TRANSTHYRETIN EXPRESSION - Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof. | 2011-12-01 |
20110294869 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE - Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions. | 2011-12-01 |
20110294870 | TREATMENT OF TUMOR SUPPRESSOR GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO THE GENE - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Tumor Suppressor genes. | 2011-12-01 |
20110294871 | LIPIDS, LIPID COMPLEXES AND USE THEREOF - The present invention is related to a compound according to formula (I), | 2011-12-01 |
20110294872 | HIGH-AFFINITY NUCLEIC ACID APTAMERS AGAINST SCLEROSTIN PROTEIN - Described are nucleic acid aptamers that are able to bind to and inhibit the function of sclerostin, which is an important negative regulator of bone growth. The aptamers have application as therapeutics for diseases of bone including osteoporosis, osteopenia, osteoarthritis and other osteoporosis-related conditions and complications. | 2011-12-01 |
20110294873 | Gene Transfer Vectors Comprising At Least One Isolated DNA Molecule Having Insulator Or Boundary Properties And Methods To Identify The Same - The present invention relates to gene transfer vectors and in particular expression vectors which comprise at least one isolated DNA molecule having insulator and or boundary properties which limits the effects of a regulatory sequence upon another regulatory or coding sequence disposed upon the other side of said at least one isolated DNA molecule. The present invention also relates to methods of identifying isolated DNA molecule having insulator and or boundary properties and to the use of expression vector, in particular a retrovirus vector, in in vivo and ex vivo gene therapy methods as well as to cells and organisms transformed using vectors according to the present invention. | 2011-12-01 |
20110294874 | DIAGNOSIS AND THERAPY OF ORGAN DYSFUNCTION USING SPHINGANINE-1-PHOSPHATE - The invention relates to the treatment and diagnosis of organ dysfunction caused by ischemia reperfusion injury. In particular, the invention relates to sphinganine-1-phosphate, a sphingolipid metabolite, and its use in the diagnosing, preventing, and/or treating ischemia reperfusion-associated disorders, including, without limitation, disorders of the kidney, liver, lung, brain, and heart. | 2011-12-01 |
20110294875 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS - The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia. | 2011-12-01 |
20110294876 | CYCLOHEXYL CARBAMATE COMPOUNDS AS ANTI-AGEING ACTIVES - The present invention relates to the cosmetic, dermatological or therapeutic use of compounds of formula (I) given below, in particular as anti-ageing actives. | 2011-12-01 |
20110294877 | TRANSITION METAL COMPLEXES OF BIS[THIOHYDRAZIDE AMIDE] COMPOUNDS - The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I), or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. In one embodiment, the compound is represented by Structural Formula (II), or a prodrug, isomer, ester, salt, hydrate, solvate or polymorph thereof. The present invention also provides a pharmaceutical composition comprising the compound of the invention and method of use thereof. | 2011-12-01 |
20110294878 | Inhibitors of Dimethylarginine Dimethylaminohydrolase - The invention relates to an inhibitor of dimethylarginine dimethylaminohydrolase (DDAH) of general structural formula (I), wherein B is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of 3 to 6; R | 2011-12-01 |
20110294879 | METHOD OF TREATMENT OF FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS - Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down's syndrome and/or autism, comprising administering a prodrug of acamprosate to a subject suffering therefrom, wherein, in certain embodiments, the acamprosate prodrugs comprise compounds of Formula (I). | 2011-12-01 |
20110294880 | PHARMACEUTICAL COMPOSITION CONTAINING PROSTAGLANDIN - An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F | 2011-12-01 |
20110294882 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES - The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions. | 2011-12-01 |
20110294883 | ALPHA-DERIVATIVES OF CIS-MONOUNSATURATED FATTY ACIDS INTENDED FOR USE AS A DRUG - Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular weight between 4 and 200 Da and (R) can be substituted by any atom or group of atoms with an atomic/molecular weight between 1 and 200 Da, for use as medicines. | 2011-12-01 |
20110294884 | Bipolar trans carotenoid salts and their uses - The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans. | 2011-12-01 |
20110294885 | CONTROLLED-RELEASE PREGABALIN COMPOSITIONS - An orally-administrable controlled-release formulation, including pregabalin or a pharmaceutically acceptable salt of pregabalin and polycarbophil, as a controlled-release agent. | 2011-12-01 |
20110294886 | CONTROLLED-RELEASE TABLET FORMULATIONS OF PREGABALIN - A controlled-release tablet formulation which gels in the stomach, including pregabalin or a pharmaceutically acceptable salt thereof, and a complex of sodium alginate and calcium chloride, or calcium alginate, or a properly-proportioned mixture thereof as a controlled-release agent. | 2011-12-01 |
20110294887 | CONTROLLED-RELEASE SOLUTION FORMULATIONS OF PREGABALIN - A controlled-release oral solution formulation, which gels in the stomach, includes pregabalin or a pharmaceutically acceptable salt of pregabalin and a gelling agent. | 2011-12-01 |
20110294888 | Use of Salts of Sulfur-Containing Compounds for Controlling Parasites - The invention relates to a method of controlling nematodes with salts of sulphur-containing compounds. | 2011-12-01 |
20110294889 | Infusion and Injection Solution of Levodopa - An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as glucose, a physiologically acceptable acid, such as hydrochloric acid, and optionally a stabilizer, and has a pH of lower than or equal to 6. There are also described a disposable syringe containing an infusion or injection solution of Levodopa, optionally together with a Levodopa-metabolising enzyme, and an infusion pump cassette containing an infusion or injection solution of Levodopa optionally together with a Levodopa-metabolising enzyme. | 2011-12-01 |
20110294890 | Neramexane for the treatment or prevention of inner ear disorders - The present invention relates to a method of treatment or prevention of an inner ear disorder in a female comprising administering a therapeutically effective amount of neramexane or a pharmaceutically acceptable salt thereof to a female. | 2011-12-01 |
20110294891 | METHODS AND COMPOSITIONS FOR TREATING OPTHALMIC CONDITIONS WITH RETINOL DERIVATIVES - Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies. | 2011-12-01 |
20110294892 | Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes - The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumor syndromes and may be from 10 to 150 mg/day/patient. | 2011-12-01 |
20110294893 | NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS - The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc. | 2011-12-01 |
20110294894 | Pharmaceutical Composition for the Treatment of Solar Urticaria - The present invention refers to a local anesthetic, preferably selected from the group of aminoamide local anesthetics, in particular lidocaine or prilocaine, for use in the treatment or prevention of physical urticaria, in particular solar urticaria. The present invention further refers to a pharmaceutical composition, e.g. a cream, comprising such a local anesthetic, in particular a combination of lidocaine and prilocaine. | 2011-12-01 |
20110294895 | BIS(THIO-HYDRAZIDE AMIDE) FORMULATION - Disclosed herein are compositions comprising a compound represented by structural formula (I): | 2011-12-01 |
20110294896 | Topical Treatment With Dapsone In G6PD-Deficient Patients - The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, and wherein the composition also contains dapsone in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The present invention also discloses the treatment of dermatological conditions in G6PD-deficient patients with the composition, while avoiding adverse hematologic effects. | 2011-12-01 |
20110294897 | Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion - Methods for the treatment of patients suffering from dry eyes, by using adrenergic beta-receptor agonists, particularly salbutamol and in particular the optically pure or substantially pure R-enantiomer thereof. The embodiments disclosed herein include methods of increasing the Meibomian lipid secretion and thereby reducing or eliminating xerophthalmia symptoms by the administration of formulations containing therapeutically effective amounts of an adrenergic beta-receptor agonist to said patients. In particular, certain embodiments disclosed herein concern compositions that contain R-salbutamol as the active beta-receptor stimulating ingredient. In certain embodiments, the formulations are administered to the ocular surface of the eye and/or to the eyelid (the underside of the eyelid and/or the top of the eyelid) of a patient in need thereof. | 2011-12-01 |
20110294898 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol Hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 2011-12-01 |
20110294899 | DEFOAMER COMPOSITION COMPRISING ALKOXYLATED 2-PROPYLHEPTANOL - The present invention relates to defoaming compositions comprising compounds having the formula C | 2011-12-01 |
20110294900 | SELF EMULSIFYING DRUG DELIVERY SYSTEM FOR A CURCUMINOID BASED COMPOSITION - The present invention discloses a pharmaceutical composition in the form of self nano emulsifying drug delivery formulation comprising curcuminoids. The pharmaceutical composition of the present invention shows an enhanced drug loading ability, better stability and an improved bioavailability. The composition of the present invention comprises of a pharmaceutically effective amount of a curcuminoid, an oil phase, a surfactant and a co surfactant. | 2011-12-01 |
20110294901 | FINELY PULVERIZED PHARMACEUTICAL COMPOSITION - An objective of the present invention is to provide a composition that has improved oral absorption and comprises a slightly soluble drug, and to provide a process for producing the same. According to the present invention, there is provided a finely pulverized composition comprising a slightly soluble drug such as 22β-methoxyolean-12-ene-3β, 24(4β)-diol and a hydrophilic surfactant. According to the present invention, there is also provided a process for producing the finely pulverized composition according to the present invention, characterized in that, after the dispersion of a slightly soluble drug and a hydrophilic surfactant in a solvent, the dispersion is pulverized with a high-pressure homogenizer. | 2011-12-01 |
20110294902 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS - A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer. | 2011-12-01 |
20110294903 | LARGE PARTICLE SIZE CRYSTALLISED MALTITOL POWDER, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF, PARTICULARLY IN CHOCOLATE PRODUCTION - A crystallized maltitol powder including a maltitol content greater than 99.5% by weight, characterized by a particle-size distribution by volume, determined by laser granulometry, having less than 20% particles less than 200 μm in size, less than 6% particles less than 100 μm in size, less than 2% particles less than 40 μm in size and a pour value less than or equal to 10 seconds, an aerated density greater than 0.85 g/ml, a compacted density greater than 0.97 g/ml, and a compressibility of less than 17%, and to its use in the pharmaceuticals and above all foods sectors, in particular in the formulation of chocolates or table sweeteners. | 2011-12-01 |
20110294904 | Dry Granulation Binders, Products, and Use Thereof - A method for the preparation of microcrystalline cellulose containing tablets by roller compaction followed by tabletting is disclosed. A tablet formulation is converted to a dry granulate by roller compaction, and the dry granulate lubricated dry granulate and compacted to a tablet. The tablet formulation comprises at least one active, an microcrystalline cellulose containing material, and, optionally other pharmaceutically acceptable excipients. The microcrystalline cellulose containing material has a maximum primary compaction tensile strength of at least 9 MPa or at least 9.5 MPa and a secondary compaction tensile strength of at least 5 MPa, at least 5.5 MPa, or at least 6 MPa. A method for evaluating binders is also disclosed. | 2011-12-01 |
20110294905 | Conversion Of Liquid Heavy Hydrocarbon Feedstocks To Gaseous Products - The present invention relates to processes and apparatuses for generating light olefins, methane and other higher-value gaseous hydrocarbons from “liquid” heavy hydrocarbon feedstocks. | 2011-12-01 |
20110294906 | INCORPORATION OF CATALYTIC DEHYDROGENATION INTO FISCHER-TROPSCH SYNTHESIS TO LOWER CARBON DIOXIDE EMISSIONS - A method for producing liquid fuels includes the steps of gasifying a starting material selected from a group consisting of coal, biomass, carbon nanotubes and mixtures thereof to produce a syngas, subjecting that syngas to Fischer-Tropsch synthesis (FTS) to produce a hyrdrocarbon product stream, separating that hydrocarbon product stream into C1-C4 hydrocarbons and C5+ hydrocarbons to be used as liquid fuels and subjecting the C1-C4 hydrocarbons to catalytic dehydrogenation (CDH) to produce hydrogen and carbon nanotubes. The hydrogen produced by CDH is recycled to be mixed with the syngas incident to the FTS reactor in order to raise the hydrogen to carbon monoxide ratio of the syngas to values of 2 or higher, which is required to produce liquid hydrocarbon fuels. This is accomplished with little or no production of carbon dioxide, a greenhouse gas. The carbon is captured in the form of a potentially valuable by-product, multi-walled carbon nanotubes (MWNT), while huge emissions of carbon dioxide are avoided and very large quantities of water employed for the water-gas shift in traditional FTS systems are saved. | 2011-12-01 |
20110294907 | GENERATING METHANOL USING ULTRAPURE, HIGH PRESSURE HYDROGEN - In various implementations, methanol is produced using a (CO+H | 2011-12-01 |
20110294908 | FISCHER-TROPSCH SYNTHESIS FE-BASED CATALYST, PROCESS OF PREPARATION AND APPLICATION THEREOF - This invention relates to a Fe-based catalyst for Fischer-Tropsch synthesis, preparation method and application thereof. The catalyst contains Fe, oxide(s) of IB group metal Cu and/or Ag as a reducing promoter, IA group metal Li, Na, K or Rb as an electron promoter, VIII group noble metal Ru, Rh, Pd or Pt as a hydrogenation promoter and SiO | 2011-12-01 |
20110294909 | PROCESS FOR ADDING A COUPLING AGENT TO RAW STOCK - The invention relates to a process for manufacturing composite material which contains fiber based and polymer based material, wherein the manufacture includes a preliminary treatment process to form a raw stock mixture. According to the invention, the preliminary treatment process includes a hot-cold mixing device which comprises at least a heating stage, and that raw stock, which contains lignin-free material, and a coupling agent are fed to the mixing device to form the raw stock mixture, and adhesion between fiber based and polymer based substances of the raw stock is ameliorated by the coupling agent. | 2011-12-01 |
20110294910 | EXPANDABLE PELLETIZED POLYAMIDE MATERIAL - An expandable pelletized material comprising
| 2011-12-01 |
20110294911 | POLYURETHANE SURFACTANT STABILIZED POLYURETHANE FOAMS - The invention relates to the production of hydrophilized polyurethane foams, especially for wound treatment, wherein a composition containing a polymer and special polyurethane-based stabilizers is expanded and dried. | 2011-12-01 |
20110294912 | REINFORCED THERMOPLASTIC MOLDING COMPOSITIONS BASED ON POLYARYLENE ETHERS - The present invention relates to thermoplastic molding compositions composed of the following components:
| 2011-12-01 |
20110294913 | FLEXIBLE MATERIAL FOR SURFACE ADHESIVE RULE - A flexible material that comprises one or more types of polymers and may be used for drawing surface-adhesive rules having a pre-defined cross-section profile. Wherein the flexible material has attribute to reserve a shape of a profile of an orifice through which it is deposited from. | 2011-12-01 |
20110294914 | WETTABLE HYDROGELS COMPRISING ACYCLIC POLYAMIDES - The present invention relates to biomedical devices, and particularly contact lenses comprising a polymer having entangled therein at least one acyclic polyamide. | 2011-12-01 |
20110294915 | RUBBER COMPOUND CONTAINING A BLOCKED MERCAPTOSILANE COUPLING AGENT - The invention relates to a rubber compound containing no or less than 0.5 phr zinc, which can be used for the manufacture of tyres, the compound being based on at least: a diene elastomer; a sulphur-based crosslinking system; an inorganic filler as reinforcing filler; and a blocked mercaptosilane of the following general formula (I) in which formula (I): R | 2011-12-01 |
20110294916 | HYDROPHILIC MARKING FILM HAVING PLASMA CHEMICAL VAPOR DEPOSITION TREATED PROTECTIVE LAYER - The present application relates to a hydrophilic marking film having both hydrophilicity at the time of application and stable hydrophilicity over time, the hydrophilic marking film having excellent weather resistance properties such as color difference, gloss retention, and the like, and excellent contamination resistance properties. The hydrophilic marking film is provided with a film and a protective layer, wherein the protective layer contains 10% or more but less than 40% of carbon, more than 45% but not more than 75% of oxygen and 15% or more but not more than 32% of silicon in terms of atomic composition and is formed by a plasma CVD method. | 2011-12-01 |
20110294917 | USE OF RECYCLED PLASTICS FOR STRUCTURAL BUILDING FORMS - Modular plastic structural composites formed from a mixture of (A) high density polyolefin and one or both of: (B) a thermoplastic-coated fiber material, or (C) polystyrene, poly(methyl methacrylate), or a combination thereof. Composites molded in the form of I-Beams and bridges constructed therefrom are also disclosed. | 2011-12-01 |
20110294918 | ANTI-CORROSIVE PAINTINGS AND COATINGS CONTAINING NANOPARTICLES - The present invention refers to a formulation for anticorrosion paints and coatings, based on epoxy, polyurethane, acrylic, alkylic, polyester resins and mixtures thereof, dissolved in organic or inorganic solvent and comprising a multitude of mostly bi-dimensionally developed nanoparticles, with a few hundred and about one nanometer, respectively, as to lateral dimensions and thickness, wherein the viscosity of the formulation is lower than 55000 mPa·s. | 2011-12-01 |
20110294919 | Coating Composition and Cured Film Formed Therefrom - A coating composition comprises a first copolymer and a second copolymer. The first copolymer has at least one linear polymer strand having a weight average molecular weight of at least 1,500 Daltons and functionality X with an equivalent weight of no more than 500. The second copolymer has at least one linear polymer strand having a weight average molecular weight of at least 1,500 Daltons and functionality X′ with an equivalent weight of no more than 1,500. The coating composition is free of gloss flattening agents, yet still produces a cured film having a low gloss of less than 70 gloss units at an angle of incidence of 60°, as measured according to ASTM D 2457. | 2011-12-01 |
20110294920 | DOPO-FLAME RETARDANT IN EPOXY RESINS - The present invention relates to flame retardant polymer compositions which comprise mixtures of phosphinic acid salts and dihydrophospho-phenantrene (DOPO). The mixtures are especially useful for the manufacture of flame retardant compositions based on polyfunctional epoxides and epoxy resin compositions that result in laminates with excellent surface characteristics and reduced delamination tendency. | 2011-12-01 |
20110294921 | FUSION BONDED EPOXY COATING COMPOSITIONS THAT INCLUDE MAGNESIUM OXIDE - A powdered epoxy coating composition for coating a substrate. The coating composition comprises: (a) from about 50 wt % to about 90 wt % of at least one epoxy resin; (b) from about 1 wt % to about 30 wt % of at least one catechol novolak-type adhesion promoter; and (c) from about 0.1 wt % to about 5 wt % of magnesium oxide. The coating may also include from about 10 wt % to about 48 wt % of an inorganic filler. The coating composition provides improved adhesion at high temperature operating conditions and improved resistance to damage by cathodic disbondment for pipe, rebar, and other substrates. | 2011-12-01 |
20110294922 | ENCAPSULATION OF PHOSPHORUS PENTASULFIDE - A method of treating or encapsulating phosphorus pentasulfide so that it can be safely handled, stored and transported. The treating or encapsulating involves combining the phosphorus pentasulfide with a hydrocarbon oil under high shearing conditions. The hydrocarbon oil can be a mineral oil such as a paraffinic oil. The encapsulated phosphorus pentasulfide is pumpable and, according to one embodiment, is used as a modifier/crosslinking agent in asphalt mixtures. | 2011-12-01 |
20110294923 | Polymerization Mixture That Can Be Produced Without Water - The invention relates to a process for the preparation of a polymerization mixture suitable as a dispersant and comprising a copolymer. In the process, a vinyloxyalkylpolyether derivative is reacted with an acid monomer derivative with formation of the copolymer in the presence of a free radical polymerization initiator by free radical polymerization, the free radical polymerization taking place in a medium which contains less than 25% by weight of water and in totality more than 60% by weight of copolymer, vinyloxyalkylpolyether derivative and acid monomer derivative. | 2011-12-01 |
20110294924 | Methods of Production of Alkylstyrene/Isoolefin Polymers - Copolymer are formed by polymerizing C | 2011-12-01 |
20110294925 | COMPOSITE FROM HEMICELLULOSE EXTRACTED WOOD WITH IMPROVED PERFORMANCE AND REDUCED EMISSIONS - A composite article includes cellulosic strands and binder, the strands having been extracted to remove hemicellulose. In certain embodiments, the cellulosic strands are wood strands. The article may have reduced production of volatile organic compound emissions compared to the same article made with non-extracted strands. Also, the article may have improved performance after exposure to moisture. A method of manufacturing a composite article comprising extracting cellulosic strands to remove hemicelluose, and forming a composite which includes the strands and a binder. In certain embodiments, the extraction is a hot water extraction. | 2011-12-01 |
20110294926 | BINDER FOR GRANULAR AND/OR FIBROUS SUBSTRATES - Binder for granular and/or fibrous substrates | 2011-12-01 |
20110294927 | BIO-OIL FORMULATION AS AN ASPHALT SUBSTITUTE - A bio-oil formulation, useful as an asphalt binder substitute in pavement and roofing shingles, includes bio-oil and a polymer additive. The bio-oil binder can include an asphalt additive. The bio-oil binder can be emulsified with water and a surfactant for use as a weatherproofing sealant or as an adhesive. A method for making the bio-oil binder is disclosed. | 2011-12-01 |
20110294928 | POLYCARBONATE RESIN COMPOSITION - Provided is a polycarbonate resin composition which has: a high degree of biomass (degree of vegetation); is excellent in environmental performance; has high fluidity and high impact resistance; is excellent in flame retardancy and heat resistance; and further provides a molded body excellent in molding appearance, by blending (B) a lignophenol at a specific ratio into (A) a polycarbonate resin or a resin mixture formed of the component (A) and (C) a polylactic acid and/or a copolymer containing a polylactic acid. | 2011-12-01 |
20110294929 | MATERIALS, METHODS FOR PRODUCTION THEREOF AND COMPONENTS THEREOF - The present invention relates to materials comprising
| 2011-12-01 |
20110294930 | FLAME RETARDANT THERMOPLASTIC ELASTOMERS - The invention relates to a thermoplastic elastomer composition comprising a thermoplastic elastomer and a flame retardant, wherein the flame retardant comprises at least a compound selected from the group consisting of piperazine phosphate, piperazine pyrophosphate and piperazine polyphosphate, and a phosphoric acid compound. | 2011-12-01 |
20110294931 | LIQUID FILM BASED ON SILANE-TERMINATED POLYMERS - A composition that includes at least one silane-functional polymer P and 20 to 60% by weight of aluminum hydroxide or magnesium hydroxide or mixture thereof, is disclosed. The composition has a viscosity of 500 to 20,000 mPa·s measured according to DIN 53018 at a temperature of 20° C. The composition is suitable as a liquid membrane and has very good flammability properties, i.e., it is difficult to ignite and is self-extinguishing. | 2011-12-01 |
20110294932 | COMPOSITION AND METHOD FOR PROVIDING STAIN RELEASE OR STAIN REPELLENCY TO SUBSTRATES - The present invention provides a composition for treatment, the composition comprising dispersed in water (i) a fluorinated compound, (ii) a potassium or lithium silicate and (iii) an acrylic polymer. The invention further provides a method of treating substrates with the composition. | 2011-12-01 |
20110294933 | POLYHYDROXYFUNCTIONAL POLYSILOXANES FOR INCREASING THE SURFACE ENERGY OF THERMOPLASTICS, METHOD FOR PRODUCTION AND USE THEREOF - The invention relates to polyhydroxyfunctional polysiloxanes, which may be produced by the addition of at least one branched polyhydroxyfunctional allyl polyether to a Si—H functional alkyl polysiloxane, to methods for production thereof and the use thereof as additives in thermoplastics and polymeric moulded masses and the thermoplastics and polymeric moulded masses containing the same. | 2011-12-01 |
20110294934 | TWO-COMPONENT COATING COMPOSITIONS FOR FLEXIBLE COATINGS - The invention relates to coating systems for producing fast-drying flexible coatings which are based on aromatic allophanate group-containing prepolymers and aliphatic polyisocyanates and aminofunctional polyaspartic esters as the curing agents. | 2011-12-01 |
20110294935 | METHOD FOR PREPARING AN ESTER AND BINDER SYSTEM - In a method for preparing an ester from an hydroxybenzoic acid and a fatty alcohol for use in a binder system for powder injection molding, transesterification of an ester of the hydroxybenzoic acid and a low alcohol using the fatty alcohol is carried out, the fatty alcohol and the ester of the hydroxybenzoic acid and the low alcohol forming a reaction mixture and being used in an essentially equimolar ratio. The transesterification is carried out at a temperature at which the ester of the hydroxybenzoic acid and the low alcohol and the fatty alcohol are present as a homogeneous melt. The binder system for a powder injection molding contains 80 to 98 wt. % of a metal powder and/or a ceramic powder and 1 to 19 wt. % of a polymeric binder component, and 1 to 19 wt. % of at least one ester prepared by the transesterification. | 2011-12-01 |
20110294936 | TIRE TREAD RUBBER COMPOSITION AND PNEUMATIC TIRE USING THE SAME - A tire tread rubber composition includes: 100 parts by mass of diene rubber; 60 to 110 parts by mass of specific silica; and a mixture of a fatty acid metal salt (excluding zinc salt) and a fatty acid ester in which a mass ratio to the specific silica is 2 to 8 mass %, in which the diene rubber contains not less than 40 parts by mass of solution-polymerization SBR, the solution-polymerization SBR includes a weight-average molecular weight of 900,000 to 1,500,000 and a styrene content of 35 to 45%, and the specific silica satisfies the following conditions of (1) to (4): (1) N | 2011-12-01 |
20110294937 | METHOD FOR IMPROVING FLOWABILITY OF RANDOM POLYPROPYLENE POWDER - Method for the preparation of a sticky random propylene copolymer (R-PP) in a reactor facility comprising in series (i) a first reaction system, (ii) a first conveying line connecting the first reactor system with a second reactor system comprising an outlet, (iii) a second conveying line connecting the outlet with a purge bin comprising a feeder, and (iv) a conveying system being connected with the feeder, and the preparation of said random propylene copolymer (R-PP) comprises the steps in the order of (a) producing in said first reactor system a propylene homopolymer (H-PP) or a random propylene copolymer (R-PP1), (b) transferring at least a part of said polypropylene to said second reactor system via the first conveying line, (c) producing in said second reactor system a random propylene copolymer (R-PP2) obtaining the random propylene copolymer (R-PP), (d) discharging said random propylene copolymer (R-PP) from said second reactor system via the outlet, (e) transferring said discharged random propylene copolymer (R-PP) via the second conveying line to said purge bin comprising said feeder, and (f) transferring further said discharged random propylene copolymer (R-PP) from said purge bin via said feeder to said conveying system, the produced random propylene copolymer (R-PP) is provided with an additive, said additive is fed to the produced random propylene copolymer (R-PP) (α) at the outlet of the second reactor system, or (β) at the feeder (F) of the purge bin (PB). | 2011-12-01 |
20110294938 | Perfluoroelastomer - A peroxide curable perfluoroelastomer comprising: recurring units derived from tetrafluoroethylene (TFE); and recurring units derived from perfluoromethylvinylether (MVE); such perfluoroelastomer possessing a Mooney Viscosity (ML2+9) at 121° C. of from 25 to 140 MU, when measured according to ASTM D1646 standard, and comprising such MVE recurring units in an amount of from 26 to 33% by moles with respect to total moles of TFE and MVE. A process for the manufacture of such perfluoroelastomer, and cured articles obtainable therefrom. | 2011-12-01 |
20110294939 | Elastomeric Nanocomposite Manufacturing - An elastomeric nanocomposite is produced from an isobutylene-based polymer and a layered nanofiller. The process of preparing the nanocomposite includes the steps of a) polymerizing isobutylene monomers and multiolefin monomers to produce an isobutylene-based polymer; b) completing at least one mass transfer dependent stage in the process wherein, after completion of the stage and prior to any recovery of the polymer, the polymer is dissolved in a solvent to create a polymer cement; c) contacting the layered nanofiller and the polymer solvent to obtain the nanocomposite; and d) recovering the nanocomposite. The layered nanofiller may be in a slurry prior to contacting with the polymer cement. | 2011-12-01 |
20110294940 | METHOD FOR IMPROVING FLOWABILITY OF HETEROPHASIC POLYPROPYLENE POWDER - Method for the preparation of a sticky high impact heterophasic polypropylene (HECO) in a reactor facility comprising in series (i) a first reaction system, (ii) a first conveying line connecting the first reactor system with a second reactor system comprising an outlet, (iii) a second conveying line connecting the outlet with a purge bin comprising a feeder, and (iv) a conveying system being connected with the feeder, and the preparation of said heterophasic polypropylene (HECO) comprises the steps in the order of (a) producing in said first reactor system the polypropylene matrix (M), (b) transferring at least a part of said polypropylene to said second reactor system via the first conveying line, (c) producing in said second reactor system the elastomeric copolymer obtaining the heterophasic polypropylene (HECO), (d) discharging said heterophasic polypropylene (HECO) from said second reactor system via the outlet, (e) transferring said discharged heterophasic polypropylene (HECO) via the second conveying line to said purge bin comprising said feeder, and (f) transferring further said discharged heterophasic polypropylene (HECO) from said purge bin via said feeder to said conveying system, the produced heterophasic polypropylene (HECO) is provided with an additive, said additive is fed to the produced heterophasic polypropylene (α) at the outlet of the second reactor system, or (β) at the feeder (F) of the purge bin (PB). | 2011-12-01 |
20110294941 | VINYL CHLORIDE-BASED RESIN COMPOSITION, METHOD OF PRODUCING VINYL CHLORIDE-BASED POLYMER COMPOSITION, AND VINYL CHLORIDE-BASED POLYMER COMPOSITION OBTAINED THEREBY - Provided is a vinyl chloride-based resin composition including a vinyl chloride-based resin and a titanium dioxide having an average particle diameter of 5 to 50 nm, in an amount of 1,000 ppm to 10,000 ppm, by mass, relative to the mass of the vinyl chloride-based resin. By adding a titanium dioxide having an average particle diameter of 5 to 50 nm to a vinyl chloride-based resin in an amount described above, a vinyl chloride-based resin composition of excellent thermal stability can be obtained. In the vinyl chloride-based resin composition, the crystalline form of the titanium dioxide is preferably anatase, rutile, or a combination thereof. Also provided is a method of producing a vinyl chloride-based polymer composition that includes subjecting a vinyl chloride monomer, or a mixture of a vinyl chloride monomer and a monomer that is copolymerizable therewith, to suspension polymerization within an aqueous medium, and also includes adding a titanium dioxide having an average particle diameter of 5 to 50 nm to the raw material prior to commencement of the polymerization, to the reaction mixture during the polymerization, to the reaction product following completion of the polymerization, or to a combination of two or more of the raw material, the reaction mixture and the reaction product. The vinyl chloride-based polymer composition obtained using this method exhibits excellent thermal stability. | 2011-12-01 |
20110294942 | PIGMENT DISPERSIONS, RELATED COATING COMPOSITIONS AND COATED SUBSTRATES - Disclosed are pigment dispersions and coating compositions that include such pigment dispersions. The pigment dispersions include: (a) a pigment; (b) an acid functional, hydroxyl functional and secondary amine functional acrylic polymer having a weight average molecular weight of at least 11,000; and (c) a liquid carrier comprising an organic solvent. | 2011-12-01 |
20110294943 | FIBERS SIZED WITH POLYETHERKETONEKETONES - Fibers sized with a coating of amorphous polyetherketoneketone are useful in the preparation of reinforced polymers having improved properties, wherein the amorphous polyetherketoneketone can improve the compatibility of the fibers with the polymeric matrix. | 2011-12-01 |
20110294944 | Perfluoroelastomer - A peroxide curable perfluoroelastomer comprising: recurring units derived from tetrafluoroethylene (TFE); recurring units derived from perfluoroethylvinylether (EVE), in an amount of between 2 and 17% by moles, with respect to total recurring units derived from TFE, perfluoromethylvinylether (MVE) and EVE; and recurring units derived from perfluoromethylvinylether (MVE), in an amount of between 23 and 35% by moles, with respect to total recurring units derived from TFE, perfluoromethylvinylether (MVE) and EVE. A process for its manufacture and its use for the manufacture of cured articles. | 2011-12-01 |